CN107406430A - 喹唑啉衍生物的盐及其制备方法 - Google Patents

喹唑啉衍生物的盐及其制备方法 Download PDF

Info

Publication number
CN107406430A
CN107406430A CN201680015924.6A CN201680015924A CN107406430A CN 107406430 A CN107406430 A CN 107406430A CN 201680015924 A CN201680015924 A CN 201680015924A CN 107406430 A CN107406430 A CN 107406430A
Authority
CN
China
Prior art keywords
formula
compound
maleate
preparation
maleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680015924.6A
Other languages
English (en)
Other versions
CN107406430B (zh
Inventor
张喜全
汤松
丰巍伟
田心
陈智林
顾红梅
徐宏江
刘飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN107406430A publication Critical patent/CN107406430A/zh
Application granted granted Critical
Publication of CN107406430B publication Critical patent/CN107406430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本申请涉及式I化合物的马来酸盐、其制备方法、其药物组合物及其在***如非小细胞肺癌、乳腺癌等多种恶性肿瘤中的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201680015924.6A 2015-03-20 2016-03-18 喹唑啉衍生物的盐及其制备方法 Active CN107406430B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015101259624 2015-03-20
CN201510125962 2015-03-20
PCT/CN2016/076693 WO2016150340A1 (zh) 2015-03-20 2016-03-18 喹唑啉衍生物的盐及其制备方法

Publications (2)

Publication Number Publication Date
CN107406430A true CN107406430A (zh) 2017-11-28
CN107406430B CN107406430B (zh) 2019-04-26

Family

ID=56977000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015924.6A Active CN107406430B (zh) 2015-03-20 2016-03-18 喹唑啉衍生物的盐及其制备方法

Country Status (8)

Country Link
US (1) US10231973B2 (zh)
EP (1) EP3272746B1 (zh)
JP (1) JP6704422B2 (zh)
CN (1) CN107406430B (zh)
ES (1) ES2775614T3 (zh)
HK (1) HK1244278B (zh)
RU (1) RU2720810C2 (zh)
WO (1) WO2016150340A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627731A (zh) * 2019-10-09 2019-12-31 贵州大学 一类4-氨基喹唑啉接丙烯酰胺类化合物及其制备方法和应用
CN114401957A (zh) * 2019-09-04 2022-04-26 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN114761010A (zh) * 2019-11-25 2022-07-15 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858340B2 (en) * 2016-08-25 2020-12-08 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Crystal of salt of quinazoline derivative
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
US20220242851A1 (en) * 2019-06-19 2022-08-04 Shenzhen Jinrui Foundation Biotech Co., Ltd Crystal form and salt of quinazoline compound and preparation method thereof
WO2021083347A1 (zh) * 2019-11-01 2021-05-06 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐、或其药物组合物的用途
EP4052713A1 (en) * 2019-11-01 2022-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising quinazoline derivative or salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878203A (zh) * 2007-10-29 2010-11-03 纳科法尔马有限公司 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物
CN103948689A (zh) * 2014-04-15 2014-07-30 西北农林科技大学 用于治疗非小细胞肺癌的药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CZ20011759A3 (cs) 1998-11-19 2002-01-16 Warner-Lambert Company N-[4-(3-chlor-4-fluor-fenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl]-akrylamid, ireversibilní inhibitor tyrosin-kinas
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PL1667992T3 (pl) 2003-09-19 2007-05-31 Astrazeneca Ab Pochodne chinazoliny
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
WO2007055513A1 (en) 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
WO2008002039A1 (en) 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
AU2012311184A1 (en) 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878203A (zh) * 2007-10-29 2010-11-03 纳科法尔马有限公司 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物
CN103948689A (zh) * 2014-04-15 2014-07-30 西北农林科技大学 用于治疗非小细胞肺癌的药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
孙伟民等: "吉非替尼合成研究进展", 《精细与专用化学品》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114401957A (zh) * 2019-09-04 2022-04-26 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN114401957B (zh) * 2019-09-04 2023-11-21 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN110627731A (zh) * 2019-10-09 2019-12-31 贵州大学 一类4-氨基喹唑啉接丙烯酰胺类化合物及其制备方法和应用
CN114761010A (zh) * 2019-11-25 2022-07-15 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途
CN114761010B (zh) * 2019-11-25 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Also Published As

Publication number Publication date
RU2017132330A3 (zh) 2019-07-24
CN107406430B (zh) 2019-04-26
JP2018508583A (ja) 2018-03-29
JP6704422B2 (ja) 2020-06-03
WO2016150340A1 (zh) 2016-09-29
US20180085369A1 (en) 2018-03-29
HK1244278B (zh) 2020-04-17
RU2720810C2 (ru) 2020-05-13
RU2017132330A (ru) 2019-04-22
EP3272746B1 (en) 2019-12-25
EP3272746A1 (en) 2018-01-24
US10231973B2 (en) 2019-03-19
ES2775614T3 (es) 2020-07-27
EP3272746A4 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
CN107406430B (zh) 喹唑啉衍生物的盐及其制备方法
KR102075886B1 (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
WO2000020358A2 (en) NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
KR20140014313A (ko) 단백질 키나제 및 히스톤 디아세틸라제의 억제제로서 나프탈렌 카르복스아미드 유도체, 그 제조 방법 및 용도
CN107848974A (zh) 芳族磺酰胺衍生物
JP2002535318A (ja) キナーゼ阻害薬
CN105980377B (zh) 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物
CN109879877A (zh) 一种可降解plk1和brd4蛋白的化合物及其应用
CN102250202A (zh) 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用
JP2009534458A (ja) アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用
CN108350006A (zh) 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途
EA029144B1 (ru) Производные азахиназолин карбоксамида
CN103254130A (zh) 吖啶衍生物及其制备方法和用途
CN103382182B (zh) 苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
CN114133390A (zh) 一种去氢骆驼蓬碱衍生物及其制备方法和应用
CN108602779A (zh) 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
WO2007055513A1 (en) Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
CN109516984B (zh) 一种2-巯基-5-氰基嘧啶类衍生物及其制备方法和应用
CN104926804B (zh) 一类具有抗肿瘤作用的化合物、其制备方法和用途
EP3760633A1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
CN108358927A (zh) 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用
EP2832733B1 (en) 4-alkanoylamino-3-pyrazolone derivative
CN110167554A (zh) 一种具有抗癌作用的化合物及其制备方法和应用
CN105829304B (zh) N,n’取代哌啶胺类化合物、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244278

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190528

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Co-patentee after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Co-patentee before: Beijing Centaurus Biopharma Technology Co., Ltd.

Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: Shouyao holding (Beijing) Co.,Ltd.

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

CP01 Change in the name or title of a patent holder